Drug intelligence / Profile preview

K436

Development stage: Preclinical
Lead developer: Claritas Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**K436** is a synthetic form of cannabidiol (CBD), a non-psychoactive cannabinoid derived from cannabis. Developed by Kalytera Therapeutics, it is being investigated for its potential bone healing properties in preclinical studies conducted in collaboration with Ramot at Tel Aviv University. CBD and its analogs are known to interact with the endocannabinoid system, potentially modulating inflammation, cell proliferation, and tissue repair processes relevant to bone regeneration, though specific mechanisms and indications for K436 remain under exploration.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on K436.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K436.

Explore the full profile